Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine

Gene Therapy

Volumn 4, Issue 9, 1997, Pages 969-976

  Okamoto, T ^a   Kaneda, Y ^b   Yuzuki, D ^a   Huang, S K S ^a   Chi, D D J ^a   Hoon, D S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Antibody; Cancer; Gene therapy; Liposome; Vaccine

Indexed keywords

CANCER VACCINE; CROSS REACTING ANTIBODY; LIPOSOME; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENCAPSULATION; GENE; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOBLOTTING; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL;

EID: 0030825069     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300490     Document Type: Article

References (28)

1. Michel ML et al. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995; 92: 5307-5311.
2. Huygen K et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med 1996; 2: 893-898.
3. Wang B et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 4156-4160.
4. Wolff JA et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1: 363-369.
5. Hoon DSB, Irie RF. Current status of melanoma vaccines. Can they control malignant melanoma? BioDrug 1997; 1: 66-84.
6. Cotten M, Wagner E, Birnstiel ML. Receptor-mediated transport of DNA into eukaryotic cells. Meth Enzymol 1993; 217: 618-643.
7. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA co-introduced with nuclear protein in adult rat liver. Science 1989; 243: 375-378.
8. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93: 11421-11425.
9. Yanagmara I et al. Expression of full-length human dystrophin cDNA in mdx mouse muscle by HVJ-liposome injections. Gene Therapy 1996; 3: 549-553.
10. Uchiyama A et al. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res 1993; 53: 949-952.
11. Kaneda Y. Virus (Sendai virus envelope)-mediated gene transfer. Cell Biology: A Laboratory Handbook. Academic Press: San Diego, 1994, pp 50-57.
12. Okada Y. Sendai virus-induced cell fusion. Meth Enzymol 1993; 221: 18-39.
13. Isaka Y et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996; 2: 418-123.
14. Morishita R et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
15. van der Bruggen P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
16. Hoon DSB, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995; 154: 730-737.
17. Gaugler B et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-930.
18. Hohlfield R, Engel AG. The immunobiology of muscle. Immunol Today 1994; 15: 269-274.
19. Kuhober A et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol 1996; 156: 3687-3695.
20. Morton DL et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
21. Morton DL et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 1993; 690: 120-134.
22. De Backer O et al. Structure, chromosomal location, and expression pattern of three mouse genes homologous to the human MAGE genes. Genomics 1995; 28: 74-83.
23. Carrel S et al. Monoclonal antibodies against recombinant-MAGE-1 protein identify a cross-reacting 72 kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells. Int J Cancer 1996; 67: 417-422.
24. Autran B et al. Monoclonal B-cell response to diphtheria toxoid: evidence for cross-reactive epitopes. Immunol 1987; 60: 531-538.
25. De Plaen E et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40: 360-369.
26. Conry RM et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995; 55: 1397-1400.
27. Graham RA, Burchell JM, Beverly P, Taylor-Papadimitriou J Intramuscular immunization with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumor cells. Int J Cancer 1996; 65: 664-670.
28. Hoon DSB et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109-2116.